GET DAILY SIGNALSCibus (CBUS) Narrows Year-Over-Year Loss in Q3 Despite Wider-Than-Expected Results
Key Takeaways
- Cibus, Inc. reported a third quarter 2026 net loss of $0.29 per share, wider than the $0.27 loss per share analysts had expected.
- Revenue reached $0.8 million, up from $0.6 million a year earlier but below the $1.28 million consensus estimate.
- The year-over-year loss narrowed from $0.44 per share in the third quarter of 2025, helped by cost cuts and a larger share count.
- Research and development (R&D) expense fell to $7.9 million from $10.8 million, while the operating loss narrowed to $12.5 million from $15.4 million.
- Cash and cash equivalents of $10.7 million are expected to fund operations only into early first quarter 2027, absent new financing.
- Commercial milestones advanced, including strong Latin American rice field trials and initial manufacturing of two biofragrance products.
Putting the Earnings Release in Context
CBUS is a pre-commercial agricultural biotechnology company that uses gene editing to develop crop traits and sustainable ingredients. Its quarterly reports are read less for near-term profits than for evidence that its licensing and royalty model is gaining traction. The third quarter 2026 update arrives at a pivotal moment: the company is advancing rice herbicide-tolerance traits toward a commercial agreement while ramping sustainable-ingredient manufacturing, yet it remains dependent on raising capital. With only about $10.7 million in cash, investors are weighing real commercial progress in the field against persistent liquidity pressure, making each earnings release an important checkpoint on both the science and the balance sheet. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
CBUS reported a net loss of $0.29 per share for the third quarter of 2026, compared with a $0.44 loss per share in the third quarter of 2025. The result was wider than the $0.27 loss per share that analysts had modeled. Revenue came in at $0.8 million, up from $0.6 million a year earlier but below the $1.28 million consensus estimate.
For the first nine months of 2026, revenue totaled $3.5 million versus $2.6 million in the prior-year period, and the net loss narrowed to $0.89 per share from $2.21 per share a year earlier—a period that included a $21.0 million goodwill impairment.
Cost discipline remained a highlight. R&D expense fell to $7.9 million from $10.8 million, driven by lower headcount and the wind-down of certain facilities. Selling, general, and administrative (SG&A) expense edged up to $5.4 million from $5.3 million. Loss from operations narrowed to $12.5 million from $15.4 million. However, non-cash royalty liability interest expense to related parties rose to $9.8 million from $9.0 million, reflecting a royalty liability balance that now stands at $263.4 million.
On the commercial front, the company said its HT1 and HT3 rice herbicide-tolerance traits performed well in Latin American field trials and that testing has moved into customer Interoc's own varieties in Ecuador. It also initiated manufacturing for its first two biofragrance products, with a partner confirming both ingredients are approved for use. From what I see, these operational details help offset some of the headline shortfall.
Market Reaction and Investor Sentiment
CBUS shares have historically been sensitive to earnings-related updates, and the third quarter 2026 report arrives against a backdrop of two competing narratives. On one side, the company's commercial pipeline—rice traits, biofragrances, and new crop programs—shows tangible forward progress. On the other, the company's limited cash runway and recurring capital needs keep risk elevated in the eyes of many investors.
Because both the reported loss per share and revenue came in below consensus, the immediate market interpretation is likely to focus on the shortfall relative to expectations. At the same time, the year-over-year improvement in the loss and the operational milestones could temper downside pressure. Sentiment will also be shaped by management commentary on financing plans, given that current cash is expected to carry the company only into early first quarter 2027. I’m watching this closely as the reaction unfolds.
Forward Outlook and Key Factors to Monitor
The most closely watched near-term catalyst is the rice program. CBUS is advancing toward a definitive commercialization agreement with Interoc, with results from field trials in Ecuador expected in the first quarter of 2027 and an initial commercial launch possible as early as 2028. Management estimates a roughly $200 million annual addressable royalty opportunity for its rice trait portfolio across an estimated 5 million to 7 million peak acres.
In sustainable ingredients, the company has begun manufacturing its first two biofragrance products, and management believes an eight-ingredient portfolio could represent up to approximately $100 million in peak annual revenue under a direct-sales model. A separate partner-funded mustard program in India also began work during the quarter, adding another potential growth avenue.
Liquidity remains the central risk. With $10.7 million in cash expected to fund operations only into early 2027, investors should watch for signs of additional financing, which could involve shareholder dilution. The rising royalty liability interest expense, now at $9.8 million per quarter, continues to weigh on the bottom line and bears monitoring as the balance compounds.
Using Tickeron’s AI Tools for Deeper Analysis
In my own research process I often turn to Tickeron’s suite of AI tools to cross-check fundamentals and spot patterns across the agricultural biotechnology sector. One quick scan with the AI Screener helped confirm where CBUS stands relative to peers on key metrics like revenue growth and cash burn. These platforms give me an additional layer of perspective without replacing traditional due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CBUS turns negative, indicating new downward trend
CBUS saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 79 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CBUS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CBUS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CBUS's RSI Oscillator exited the oversold zone, 37 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBUS advanced for three days, in 210 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CBUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.093) is normal, around the industry mean (3.498). P/E Ratio (-0.781) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (21.692) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. CBUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement